Wang Chunmei, Li Ting, Lin Chengcheng, Qiu Xudong, Zhuang Wenyue, Li He, Feng Xingming, Du Xingxu, Sun Jinghui
Department of Pharmacology, School of Pharmacy, Beihua University, Jilin, China.
Department of Hand Surgery, Affiliated Hospital, Beihua University, Jilin, China.
J Med Food. 2025 Jul;28(7):682-693. doi: 10.1089/jmf.2024.k.0285. Epub 2025 Apr 9.
() polysaccharide (SCP) is an active ingredient from used mainly for the treatment of diabetes, owing to its antioxidant, hypoglycemic, and lipidemic-modulating activities. A rat type II diabetes mellitus model was established by giving rats a high-fat diet and streptozotocin (STZ) to investigate the protective effect of SCP against renal injury in diabetic rats. It was found in this study that fasting blood glucose, serum lipids, serum creatinine, and blood urea nitrogen levels were decreased, the insulin sensitivity was increased, and pathological injuries of the kidney were alleviated in SCP-treated groups, indicating that SCP should have a protective effect against renal injury in diabetic rats. SCP treatment reduced serum C-reactive protein and inhibited the expression of nuclear factors-κB and related inflammatory factors in the renal tissue of diabetic rats. SCP treatment also regulated the expression of Nuclear factor (erythroid-derived 2) like-2, heme oxygenase-1, and kelch-like ECH-associated protein-1, reduced serum malondialdehyde content, and increased superoxide dismutase activity. Furthermore, SCP down-regulated the expression of fibronectin, α-SMA, transforming growth factor β1, and p-Smad3, up-regulated Smad7 expression, and mitigated the collagen fiber deposition in the renal interstitium in diabetic rats. It can be concluded that the mechanism of SCP in alleviating renal injury may be related to inhibiting inflammation, increasing antioxidant stress capacity, and improving renal fibrosis in diabetic rats.
（）多糖（SCP）是一种源自[具体来源未给出]的活性成分，主要用于治疗糖尿病，因其具有抗氧化、降血糖和调节血脂的活性。通过给大鼠喂食高脂饮食并注射链脲佐菌素（STZ）建立大鼠II型糖尿病模型，以研究SCP对糖尿病大鼠肾损伤的保护作用。本研究发现，SCP治疗组的空腹血糖、血脂、血清肌酐和血尿素氮水平降低，胰岛素敏感性增加，肾脏病理损伤减轻，表明SCP对糖尿病大鼠肾损伤具有保护作用。SCP治疗降低了血清C反应蛋白水平，并抑制了糖尿病大鼠肾组织中核因子-κB及相关炎症因子的表达。SCP治疗还调节了核因子（红系衍生2）样2、血红素加氧酶-1和kelch样ECH相关蛋白-1的表达，降低了血清丙二醛含量，增加了超氧化物歧化酶活性。此外，SCP下调了糖尿病大鼠肾组织中纤连蛋白、α-平滑肌肌动蛋白、转化生长因子β1和磷酸化Smad3的表达，上调了Smad7的表达，并减轻了肾间质胶原纤维沉积。可以得出结论，SCP减轻肾损伤的机制可能与抑制炎症、提高抗氧化应激能力以及改善糖尿病大鼠肾纤维化有关。
